



ELSEVIER



www.elsevierhealth.com/journals/jinf

Recommendations for the prevention of secondary *Haemophilus influenzae* type b (Hib) disease

Shamez Ladhani ^{a,*}, Fiona Neely ^{a,b}, Paul T. Heath ^c, Bernadette Nazareth ^d, Richard Roberts ^e, Mary P.E. Slack ^f, Jodie McVernon ^g, Mary E. Ramsay ^a

^a Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK

^b Hampshire and Isle of Wight Health Protection Unit, Fusion 2, Parkway, Solent Business Park, Whiteley PO15 7AB, UK

^c Vaccine Institute and Division of Child Health, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK

^d Norfolk, Suffolk and Cambridgeshire Health Protection Unit, Kingfisher House, Kingfisher Way, Hinchingsbrooke Business Park, Huntingdon PE29 6FH, UK

^e National Public Health Service for Wales, Temple of Peace and Health, Cathays Park, Cardiff CF10 3NW, UK

^f *Haemophilus* Reference Unit, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK

^g Vaccine and Immunisation Research Group, Melbourne School of Population Health, Murdoch Childrens Research Institute, University of Melbourne, Victoria, Australia

Accepted 20 October 2008

Available online 18 January 2009

KEYWORDS

Haemophilus influenzae;
Hib;
Prevention;
Contacts;
Rifampicin

Summary *Haemophilus influenzae* serotype b (Hib) can cause severe life threatening disease in healthy individuals, with over 80% of cases in the pre-vaccine era occurring in children under five years of age. The introduction of Hib conjugate vaccine into routine childhood immunisation programmes has resulted in a dramatic reduction in the incidence of invasive Hib disease across all age groups. The objective of this paper is to update existing UK guidelines on the prevention of Hib disease among contacts of an index case by reviewing the original literature and the current epidemiology of Hib carriage and invasive disease. Household contacts of individuals who develop invasive Hib disease are at higher risk of developing secondary Hib infection themselves, particularly if the contact is a young child or is immunosuppressed. Pre-school contacts of young children with invasive Hib disease are also at higher risk of developing secondary Hib infection. Rifampicin at a dose of 20 mg/kg/day for 4 days is highly effective in eradicating pharyngeal carriage of Hib and reducing the risk of invasive Hib disease among household and pre-school contacts. Children under 10 years of age who develop invasive Hib disease should also receive rifampicin chemoprophylaxis to eliminate carriage and have Hib antibody levels tested around four weeks after infection. Hib vaccine failure cases should additionally have immunoglobulin concentrations measured and be assessed for evidence of an immune deficiency. If there is a vulnerable individual (child younger than 10 years or an

* Corresponding author. Tel.: +44 208 200 4400.

E-mail address: Shamez.Ladhani@hpa.org.uk (S. Ladhani).

immunosuppressed or asplenic individual of any age) among the household contacts of a case, all members of that household, including the index case, should receive chemoprophylaxis. All children younger than 10 years in the household should be appropriately vaccinated against Hib. Where more than one case occurs in a pre-school or primary school setting, chemoprophylaxis should be offered to all room contacts (including staff), and unimmunised and partially immunised children younger than 10 years should complete their primary immunisations, including a booster dose, as soon as possible. Families of children attending the same pre-school or primary school as an index case should be advised to seek medical advice if their child becomes unwell.

© 2008 The British Infection Society. Published by Elsevier Ltd. All rights reserved.

Introduction

Haemophilus influenzae serotype b (Hib) can cause severe life threatening disease in healthy individuals and is a major global cause of childhood meningitis, pneumonia, epiglottitis, septicaemia, cellulitis, osteomyelitis and septic arthritis.^{1–3} It is estimated that Hib causes three million cases of serious disease and 700,000 deaths annually worldwide, with a case fatality rate of around 5% in developed countries and up to 25% in developing countries.³ The organism can be carried asymptotically in the naso- and oro-pharynx and is most commonly acquired from asymptomatic carriers, rather than from cases. Individuals may transfer the organism to close contacts through airborne or droplet spread by coughing and sneezing. In the pre-vaccine era the vast majority (>80%) of invasive infections occurred in children younger than five years of age, with the highest attack rates in those younger than two years. The introduction of Hib conjugate vaccine into routine childhood immunisation programmes has resulted in a greater than 90% reduction in the incidence of invasive Hib disease, through a combination of direct and indirect (herd immunity) protection.^{4–11} Guidelines for the prevention of secondary cases of Hib in the United Kingdom were first published in 1991¹² and were updated in 1994 after the introduction of the Hib conjugate vaccine into the national infant immunisation schedule in 1992.¹³ The objective of this paper is to update existing UK guidelines on the prevention of Hib disease among contacts of an index case by reviewing the original literature and current epidemiology and control of Hib infection in the UK.

Epidemiology

Invasive Hib disease

In the pre-vaccine era, Hib was responsible for almost a thousand cases of invasive infections per year in England and Wales, mostly in children under five years of age (Table 1). Over half the cases (57%) presented with meningitis, 14% with epiglottitis, 8% with bacteraemia, 7% with cellulitis and 5% each with bone and joint infections or pneumonia.¹⁴ The overall case fatality rate was 4% and was highest in adults over 65 years of age, who often had underlying medical conditions.¹⁴ Clinical trials of Hib conjugate vaccines performed prior to licensure demonstrated excellent short-term protection against invasive Hib disease, with efficacy estimates of 83–100%.^{15–17} The UK introduced the Hib conjugate vaccine into the infant immunisation programme at two, three and four months in October 1992, alongside a catch-up campaign providing one dose of vaccine to children under 4 years of age. This resulted in a dramatic reduction in the incidence of invasive Hib disease in the age group targeted for vaccination, from 21–44/100,000 in 1991 to 0.63/100,000 in 1998 (Table 1). A significant decline in the incidence of Hib was also noted in older children and in adults,¹⁸ most likely due to a reduction in asymptomatic carriage among vaccinated children, which decreased the reservoir for infection, resulting in reduced transmission and herd protection.¹⁹

The rise in the number of cases between 2000 and 2003, particularly in children aged 1–2 years (Table 1), is considered to have occurred because of a wearing-off of the initial

Table 1 Confirmed cases of invasive Hib disease in England and Wales 1990–2006.

Age group	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
<1 year	345	300	52	16	15	9	14	7	12	15	21	19	28	16	13	12
1–4 years	458	470	165	21	18	21	16	14	20	46	74	120	90	18	27	34
1 year	230	230	59	11	9	11	3	6	6	10	33	56	27	10	11	9
2 years	115	140	48	6	7	7	5	4	5	12	22	37	28	3	10	16
3 years	78	75	37	1	1	3	5	3	4	15	14	18	23	2	5	7
4 years	35	25	21	3	1	0	3	1	5	9	5	9	12	3	1	2
5–9 years	12	22	8	11	3	7	3	0	4	5	9	22	21	16	4	2
10–14 years	16	17	10	1	2	2	0	2	0	3	2	2	7	3	7	5
15+ years	76	73	61	37	37	17	29	14	31	31	41	99	115	86	73	56
Not known	8	4	2	1	0	0	0	0	0	0	0	2	3	3	0	0
Total	915	886	298	87	75	56	62	37	67	100	148	264	264	142	124	109

catch-up programme, a greater than expected decline in vaccine effectiveness among children vaccinated in infancy and a temporary change in the diphtheria–tetanus–pertussis–Hib combination vaccine type offered to young infants.^{4,20–22}

During this period, invasive Hib disease in adults also increased to pre-vaccine rates. This increase was associated with a fall in the concentration of serum antibody to Hib in the adult population, indicating reduced immunity among unimmunised adults, possibly due to a reduction in opportunities for natural boosting of immunity to Hib in the vaccine era.¹⁸ In 2003, a Hib booster campaign targeting all children aged six months to four years was introduced and the use of whole cell pertussis DTP–Hib combination vaccine for primary immunisation was resumed.²³ In September 2006, a routine booster dose of combined Hib–Meningitis C vaccine was introduced into the national infant immunisation programme at the age of 12 months. This was accompanied by a catch-up booster campaign at school entry targeting children who would have been too young for the 2003 booster campaign and too old to receive the scheduled 12-month booster dose.²⁰

Hib carriage

Most studies on Hib carriage in the general population were performed in the pre-vaccine era, with reported carriage

rates of 0–9% (Table 2). Carriage rates were much higher in children compared with adults, although infants were less likely to be carriers than older children.^{24–28} Carriage rates increased with the number of children in the family,²⁹ and with the number of hours spent in day care centres.^{28,30–33} Following a case of Hib disease, carriage rates were substantially higher among contacts of the index case. Paediatric day care contacts had carriage rates of 10–23%,^{30,34} while household contacts had higher carriage rates of 26–32%,^{29,34–37} particularly if the household contacts were children younger than five years (carriage rate, 33–66%).^{29,32,34–36,38} Furthermore, family members of children who were colonised with Hib through contact with an index case in a day care centre were also likely to become colonised.^{29,35,36}

Hib conjugate vaccination significantly reduced asymptomatic pharyngeal carriage in both vaccinated and unvaccinated populations.^{39–43} In a serial survey of children aged 1–4 years attending playgroups, nurseries and child welfare clinics in England and Wales, prevalence of carriage fell from 4.0% (95% confidence interval (CI), 3.1–5.1%) prior to the introduction of vaccination in 1992 ($n = 1531$) to 0.70% (95% CI, 0.35–1.3%) in 1994 ($n = 1563$), and 0.0% in 1997 ($n = 458$) and 2002 ($n = 384$).⁴⁴ A UK study conducted after the increase in Hib disease reported a Hib carriage rate of 2.1% (95% CI, 0.7–6.0%) among 2–4-year-old

Table 2 Hib carriage among unvaccinated children before the introduction of routine Hib vaccination.

Country	Year	Age (years)	Population Surveyed	Number of Children	Hib Carriage Rates	Reference
Alaskan Eskimos	1981	≤5	Population-based	121	5.0%	94
China	2000	<5	Children with diarrhoea or dermatitis	214	1.9%	95
Denmark	1990	≤8	Day care centres	265	0.0%	96
Dominican Republic	1998	<4	Population-based	983	7.7%	25
England	1995	3–4	Population-based	79	6.3%	41
England and Wales	1992	1–4	Local playgroups, nurseries and child welfare clinics	1531	4.0%	44
Finland	1991	3	Child health centre	398	3.5%	40
Gambia	1992	1–2	Population-based	1992	11.8%	43
Hong-Kong Chinese	1995	≤5	Population-based	621	0.0%	97
Hong-Kong Vietnamese	1995	≤5	Population-based	300	1.3%	97
Indonesia	1998	≤2	Population-based	484	4.6%	24
Japan	1997	<4	Population-based	474	0.8%	26
		9		154	3.2%	
		13		167	3.0%	
Papua New Guinea	1993	<3	Population-based	100	9.0%	98
Swedish	1990	≤6	Random day care centre	49	8%	30
Thailand	2005	<5	Hospital outpatients	492	7.0%	27
Turkey	2000	<10	Child health clinics, day care centres and elementary schools	1382	7%	99
Turkey	2002	7–12	School students	300	3%	100
United States	1985	≤8	Day care centre	66	10%	31
United States	1979	25mo ^a	Four-day care centres	98	1.0%	65
United States	1979	18mo ^a	Child health centres, not attending day care	58	6.9%	65
Wales	1986	≤6	Routine health checks or primary schools	996	1.1%	28

^a Median age.

children ($n = 176$) in London.⁴⁵ In 2005, Hib was isolated from 4.2% of 855 children aged 6–16 years recruited from schools in Oxfordshire, while none of 385 healthy adults aged 20–40 years were carriers.⁴⁶ The introduction of the 12-month booster dose of the Hib conjugate vaccine is likely to have a further impact on population carriage of Hib.

Risk of a second episode in the index case

A second episode of invasive Hib disease in the index case is uncommon but recognised,^{47–50} and usually occurs within six months of the initial episode.⁴⁸ It is often difficult to distinguish between re-infection and relapse, which can occur even if the index case receives appropriate prophylaxis to eliminate carriage.⁴⁹ Relapses are associated with poor serum antibody response to the primary infection and persistence of the organism in the pharynx despite treatment.⁴⁹ Re-infection tends to occur several weeks to months after the primary infection.^{49,50} There are limited data on the risk of second episodes in the post-vaccine era. In the UK, only four cases with two distinct episodes of invasive Hib disease have been identified through enhanced national surveillance since 1992. Two cases aged 12 and 77 years were unvaccinated, a 6-year-old had received a catch-up dose of Hib vaccine when he developed his second infection and a 7-year-old had received three doses in infancy and a booster dose after his first episode of Hib at 5 years of age.

Risk of secondary cases

Almost all studies on secondary attack rates for invasive Hib disease were performed in the United States in the pre-vaccine era.^{51–56} Although there were minor differences in the definition of a close contact and duration of follow-up, it was possible to statistically combine studies on secondary attack rates in households where contacts had been prospectively monitored for at least 30 days and had not received any chemoprophylaxis (Table 3). On the other hand, studies involving day care centres were found to be heterogeneous and, therefore, are presented separately for each age group (Table 4). These studies demonstrated that household and day care contacts of index cases were at significantly higher risk of developing invasive Hib disease compared with the general population.^{37,54} In addition, secondary attack rates generally appear to be lower

for day care contacts than household contacts, although statistical analysis was not possible. This observation was most noticeable in two studies where there were no secondary cases among 935⁵⁷ and 1321⁵⁸ day care contacts observed. One retrospective cohort study proposed that the risk of secondary disease is almost negligible if the index case attended the day care facility for <18 h/week or if the contacts attended <25 h/week.⁵⁹ It should be noted that secondary cases among household and day care contacts can occur up to 11 months after the index case.^{53–56} However, when published studies of secondary cases among household contacts were combined, 44% presented within the first four days and 68% within eight days.^{52–55,57,58}

For both household and day care contacts, children younger than two years of age (particularly those under one year) were at greatest risk of developing secondary Hib disease, with a very low risk after the age of four years. While this observation may be true for the pre-vaccine era, there are no data on secondary attack rates in the post-vaccine era. Based on observations during the recent increase in Hib in the UK (Table 1), in the absence of good population control, susceptibility to Hib can occur at any age. It is likely, therefore, that, as a result of reduced opportunities for natural boosting following mass national immunisation campaigns for Hib¹⁸ and waning of protective antibody levels after infant immunisation (even in children receiving a booster dose of vaccine in the second year of life),^{60,61} a proportion of older children and adults may not be adequately protected against invasive Hib disease.^{5,62}

The effectiveness of chemoprophylaxis

Eradication of carriage

Chemoprophylaxis aims to reduce the risk of secondary disease in the index case and among close contacts by eliminating carriage. In randomised controlled trials, rifampicin at a dose of 20 mg/kg/day for four days eradicated pharyngeal carriage of Hib in 92–97% of contacts.^{32,35–38,63–66} A lower dose of rifampicin at 10 mg/kg/day for four days³⁷ or a shorter two-day course of 10 mg/kg/day either daily⁶⁷ or twice daily²⁹ were less effective, possibly because of a lower peak antibiotic levels.⁶⁸ However, one prospective randomised controlled trial comparing a four-day course of rifampicin (20 mg/kg a day up to a maximum of 600 mg) with a two-day course at the same

Table 3 Secondary attack rate among US household contacts within 30 days of hospitalisation of the index case. It was possible to combine studies on secondary attack rates in households because the chi-squared test for heterogeneity showed that the attack rates were not significantly different ($p = 0.4$ for any Hib disease, $p = 1.0$ for both the <2-year-old and <4/<5-year-old age groups; for Hib meningitis, $p = 0.6$ for <2-year-old, $p = 0.9$ for the <4/<5-year-old and $p = 0.10$ for the >4-year-old age group).

Age of Secondary case	Attack rate % (95% CI) ^a [numbers]			
	Any invasive Hib	Reference	Hib meningitis	Reference
<2 years	1.8 (0.04–9.4) [1/57]	51,54	3.8 (1.4–8.0) [6/159]	53,55
<4 or ≤5 years	2.0 (0.5–5.0) [4/202]	51,54	2.1 (1.1–3.5) [14/676]	52,53,55
≥4 years	0 (0–0.8) [0/479]	51	0.02 (0.001–0.13) [1/4256]	52,53

^a Binomial exact confidence intervals (CI).

Table 4 Secondary attack rate among US day care contacts within 60 days of hospitalisation of the index case of any invasive Hib disease. Studies on secondary attack rates in day care centres were found to be heterogeneous for each age group ($p = 0.011$ for the <2-year-old age group and $p = 0.003$ for the <4/<5-year-old age group) and, therefore, are presented separately.

Age of secondary case	Attack rate % [numbers]				
Reference	51, ^a	57	58	59	76
<2 years	3.2 [1/31]	0 [0/361]	0 [0/361]	2.7 [10/376]	1.7 [5/292]
<4 or ≤5 years	1.1 [1/91]	0.2 [1/487]	0 [0/960]	1.2 [6/486]	0.4 [8/2024]
≥4 years	0 [0/70]	0 [0/87]	—	—	0 [0/237]

^a Thirty days follow up.

dose reported similar rates of clearance of Hib pharyngeal colonisation (94% vs. 92%) among family contacts, with identical 95% confidence intervals (73–99%), although this study was poorly powered, with only 18 and 24 participants in the two groups, respectively. Other antibiotics including cotrimoxazole, ampicillin, cefaclor and a single dose of ceftriaxone were less effective than rifampicin.^{12,69,70} The efficacy of ciprofloxacin in eradication of Hib carriage has not been assessed, but has been shown to reach high concentrations in nasal secretions in healthy adults.⁷¹

Eradication of carriage was far more successful in families when all members were treated (97% vs. 64%; OR, 21.5; 95% CI, 3.0–103).³² However, the efficacy of eradication was significantly lower in children younger than five years, the age group at highest risk of secondary disease.^{29,36} Furthermore, re-colonisation was very common in this age group, with 22–28% of treated carriers re-colonised within 1–4 weeks of rifampicin prophylaxis.^{35,36} Rates of new acquisition of Hib among children with negative initial pharyngeal cultures were low and were significantly reduced among those receiving rifampicin prophylaxis compared with placebo for periods of up to one month after prophylaxis.^{36–38}

Eradication of carriage in the index case is also important in order to prevent a second episode of infection and to reduce transmission of the organism to susceptible contacts. Hib carriage can be demonstrated in most index cases before initiating antibiotic therapy.⁶⁶ Antibiotics such as ampicillin and chloramphenicol that were previously used to treat Hib were not effective in eradicating pharyngeal carriage,^{37,72} although one prospective study of 38 children with invasive Hib disease reported that the organism was not recovered from throat cultures of any of the children beyond 14 h after an intravenous antibiotic effective against the infecting Hib isolate (usually a combination of ampicillin with either chloramphenicol, a third generation cephalosporin or nafcillin) was initiated.⁷³ More recently, third-generation intravenous cephalosporins (cefotaxime or ceftriaxone) eradicated carriage in all 53 children with invasive Hib disease after three days.⁷⁴ However, only nine children were treated with ceftriaxone which is now often the empiric treatment of choice for serious infections in children. In adults, pooled analysis of four randomised clinical trials involving 292 patients with acute exacerbation of chronic bronchitis due to *H. influenzae* reported that treatment with moxifloxacin or macrolides reported higher bacterial carriage eradication rates at 7–37 days post-infection for moxifloxacin compared with azithromycin (96.8% vs. 84.6%, $p = 0.019$) and clarithromycin (90.1% vs. 64.2%, $p = 0.001$).⁷⁵

Prevention of second episodes

No prospective trials on the use of rifampicin to prevent a second episode of invasive Hib disease in index cases were identified. Cates and colleagues reported that seven of nine recurrent cases had received a full course of rifampicin prophylaxis.⁴⁹ The interval between first and second episodes varied from 9 to 138 days, and the sites of infection were different in the first and second episodes. Six of the eight recurrent cases that were typed were caused by indistinguishable strains, although it is not possible to determine whether these were relapses or re-infections. All except one case were under 12 months of age.

Prevention of secondary cases

All clinical trials on the use of chemoprophylaxis to prevent secondary cases were performed in the pre-vaccine era.¹² Several prospective and retrospective observational studies performed between 1960 and 1986 compared the risk of secondary disease among those who received or did not receive rifampicin.^{52,55–57,59,76} Because these studies reported only a small numbers of secondary cases, results were combined to give overall secondary attack rates in household (Table 5) and day care (Table 6) contacts. Table 6 shows that rifampicin reduces the risk of secondary disease by 94% among day care contacts in the 30–60 days following hospitalisation of the index case. Only one trial and none of the observational studies reported attack rates for household contacts (Table 5) and, although only a few children developed secondary Hib disease, none of the 20 secondary cases among household contacts^{37,52,55,56} and only one of 19 secondary cases among day care contacts had received rifampicin therapy.^{37,57,59,76} There have been anecdotal reports of failures of rifampicin prophylaxis among household and day care contacts, usually due to a combination of failure by healthcare professionals to implement rifampicin prophylaxis and poor uptake and compliance by contacts.^{77–79,35–37,63,80} Rarely, resistance to rifampicin has been reported.⁸¹ Re-colonisation after initial eradication can occur, and it has been suggested that rifampicin prophylaxis merely delays the onset of secondary disease.⁵⁹

Control of outbreaks

In a recent UK day care centre outbreak, rifampicin chemoprophylaxis administered to all child (irrespective of vaccination status) and staff contacts of two index cases

Table 5 The effectiveness of rifampicin in preventing secondary Hib disease in household contacts 30 days after hospitalisation of the index case.³⁸ The protective efficacy of rifampicin was calculated using the formula: $1 - (\text{risk with rifampicin}/\text{risk with no rifampicin})$.

Age of Secondary case	Attack rate % [numbers]		Protective efficacy of rifampicin (95% CI) ^a
	No rifampicin	Rifampicin	
<2 years	0 [0/33]	0 [0/26]	–
2–3 years	3.3 [3/92]	0 [0/69]	100 (–199–100)%
<4 years	2.4 [3/125]	0 [0/95]	100 (–194–100)%
≥6 years	0 [0/406]	0 [0/242]	–

^a Binomial exact confidence intervals (CI).

resulted in complete eradication of Hib pharyngeal carriage among contacts when re-tested a month later and no further cases of Hib disease.⁸² In addition to household and day care settings, outbreaks of Hib disease have been reported in close communities⁸³ as well as paediatric¹² and geriatric⁸⁴ hospital settings. Rifampicin chemoprophylaxis has been used with the aim of interrupting transmission in these circumstances. However, the numbers involved in these outbreaks have been small and, in most instances, chemoprophylaxis constituted only one of a number of control measures undertaken.

Use of vaccination following a case of Hib

For index cases, current UK guidelines recommend that unimmunised children younger than 10 years should be fully immunised after recovering from infection, while vaccinated children should have convalescent antibody levels measured and a booster dose of vaccine given if levels are below recommended protective levels.¹ In circumstances where antibody levels cannot be tested, the child should receive an additional Hib-containing vaccine.¹ The role of vaccinating household contacts to prevent secondary cases or control outbreaks is not known. Vaccination alone is probably ineffective in preventing outbreaks of Hib; the delay in antibody response to vaccination would not offer protection against most secondary cases, which occur within the first week after the index case. However, vaccination must be considered a valuable adjunct to chemoprophylaxis because it will boost immunity of previously vaccinated

children with waning immunity and reduce Hib carriage, thereby preventing further transmission of the organism.³⁹

Guidelines

The following guidelines on prevention of secondary disease have been developed following a review of the epidemiology of invasive Hib disease and the impact of immunisation and other interventions. The guidelines have been consulted on with paediatric infectious diseases specialists, microbiologists and public health consultants, and approved by the Health Protection Agency Pneumococcus and Hib Forum and the Health Protection Agency Vaccination Programme Board. The flowchart summarises the management of contacts following a case of invasive Hib disease in the index case (Fig. 1). The Centres for Disease Control and Prevention (CDC) grading system^{85,86} was used for all recommendations as follows:

- **Strongly recommended** on the basis of >2 consistent, well-conceived, well-executed studies with control groups or longitudinal measurements.
- **Recommended** on the basis of >1 well-conceived, well-executed, controlled, or time-series study; or >3 studies with more limited execution.
- **Indicated** on the basis of previous scientific observation and theoretic rationale, but case–controlled or prospective studies do not exist.
- **Not recommended** on the basis of published literature recommending against a practice.

Confirmed case of Hib

A confirmed case of Hib is defined as any individual who presents with clinical features of infection and Hib is isolated from a normally sterile site (RECOMMENDED). Unlike meningococcal disease, conjunctivitis is not considered to be an invasive infection for Hib.⁸⁷

Probable case of Hib

Following the dramatic fall in invasive Hib disease after the introduction of the Hib vaccine, most hospitals do not routinely perform *H. influenzae* serotyping. Instead, the isolates are usually sent to reference laboratories, resulting

Table 6 The effectiveness of rifampicin in preventing secondary Hib disease in day care contacts 30–60 days after hospitalisation of the index case. The protective efficacy of rifampicin was calculated using the formula: $1 - (\text{risk with rifampicin}/\text{risk with no rifampicin})$.

Age of Secondary case	Attack rate % [numbers]		Protective efficacy of rifampicin (95% CI) ^a	Reference
	No rifampicin	Rifampicin		
<2 years	1.51 [16/1060]	0.13 [1/799]	92 (37–99)% ($p = 0.002$)	51,57,59,76
2–3 years	0.42 [2/480]	0 [0/460]	100 (–320–100)% ($p = 0.5$)	51,57,76
≥4 years	0 [0/324]	0 [0/500]	–	57,76
≥6 years	0 [0/40]	0 [0/93]	–	51
Total	1.14 [18/1580]	0.07 [1/1352]	94 (52–99)% ($p = 0.003$)	

^a Binomial exact confidence intervals (CI).




Figure 1 Guidelines for the management of close contacts of Hib.

in a delay of up to a week before serotyping results become available. In such cases, or if serotyping facilities are not available, for the purposes of prophylaxis, a probable diagnosis of invasive Hib disease can be made if *H. influenzae* is isolated from a normally sterile site in (i) any child aged 2 months to 10 years, or (ii) a patient of any age with a clinical diagnosis of epiglottitis (INDICATED). Using this definition, 68% of children aged 2 months to 10 years and 96% of individuals with epiglottitis will have Hib disease. A lower proportion of paediatric cases reported as “bacteraemia” and “other” diagnoses are

currently due to Hib – these groups are included to simplify the definition for public health purposes – the overall probability of the isolate belonging to serotype b is ~50% (Table 7).

Vulnerable individual

A vulnerable individual is defined as (i) an immunosuppressed or asplenic person of any age (RECOMMENDED), or (ii) any child younger than 10 years of age (RECOMMENDED).

Table 7 Proportion of *H. influenzae* cases due to Hib in children aged 2 months to 10 years compared with older children and adults since the introduction of the Hib conjugate vaccine into the national immunisation programme (1993–2004).

	Proportion of cases due to Hib		
	2 months–10 years	>10 years	All Ages
Proportion of all cases	1050/1553 (67.6%)	593/2600 (22.8%)	1610/4099 (39.3%)
Clinical diagnosis			
Bacteraemia	201/377 (53.3%)	176/1000 (17.6%)	371/1365 (27.2%)
Epiglottitis	168/171 (98.3%)	109/119 (91.6%)	277/290 (95.5%)
Meningitis	469/568 (82.6%)	47/221 (21.3%)	493/763 (64.6%)
Other	212/437 (48.5%)	261/1260 (20.7%)	469/1681 (27.9%)

Household contact

A household contact is defined as any individual who has had prolonged close contact with the index case in a household type setting within seven days of the index case developing invasive Hib disease (INDICATED). Examples of a household contact include living or sleeping in the same house, boyfriends/girlfriends, and sharing a dormitory, flat or hospital ward with the index case. Other types of contact (e.g., at work or school) would not be considered close contact, but each situation should be considered on its own merit, particularly if a vulnerable contact is involved and a close contact group can be clearly defined (INDICATED).

Pre-school or primary school contact

The term “pre-school” is used synonymously with playgroup, nursery, day care or crèche. Pre-school and primary school contacts of an index case should be defined separately for each case with the aim of identifying groups at higher risk of developing secondary Hib disease and, therefore, might benefit from prophylaxis (INDICATED). Examples of pre-school or primary school contacts, therefore, may include staff and children in the same playgroup/class/school/social activity group as the index case.

Pre-school or primary school outbreak

A pre-school or primary school outbreak is considered to have occurred if two or more cases of invasive Hib disease have occurred among pre-school or primary school contacts (staff and children) within 120 days of each other (INDICATED).

Chemoprophylaxis course

Rifampicin at a dose of 20 mg/kg (maximum 600 mg) once a day for four days for adults and children older than three months is the prophylaxis of choice for eliminating carriage in the index case and among household contacts (STRONGLY RECOMMENDED) because it is highly effective (eradication rate of 92–97%) and Hib resistance to rifampicin is extremely rare (<0.1%) in the UK.⁸⁸ Infants younger than three months should receive 10 mg/kg once a day for 4 days (STRONGLY RECOMMENDED). It should be noted that the dose and duration for Rifampicin prophylaxis against

Hib are different to those recommended for prevention of meningococcal disease.⁸⁷ Pregnant and breastfeeding women should also receive rifampicin prophylaxis if there is a vulnerable individual among the household contacts (INDICATED) because the benefits of providing chemoprophylaxis to all household contacts, including pregnant and breastfeeding women, outweigh any potential risks. Patients should be made aware of interactions with other medications such as anticoagulants, anticonvulsants and particularly oral contraceptives, and possible staining of secretions, including urine. There is some evidence that third-generation intravenous cephalosporins may eliminate carriage in most cases, although published studies have been retrospective and uncontrolled, and involved a small number of cases only. Once daily intravenous or intramuscular ceftriaxone (50 mg/kg in children younger than 12 years, one gram for older children and adults) once a day for two days is, therefore, recommended as an alternative agent in an individual who is unable to tolerate or develops an adverse reaction to rifampicin (RECOMMENDED). Potential side effects of rifampicin include diarrhoea, hepatic dysfunction and blood disorders. Treatment courses of oral ciprofloxacin (500 mg in adults and children older than 12 years, 250 mg for children aged 5–12 years, 125 mg for children 2–4 years) twice a day for five days or azithromycin (10 mg/kg, maximum dose 500 mg) once a day for three days may be used as alternatives, but their effectiveness in eradicating Hib colonisation among healthy individuals has not been determined (INDICATED). The use of ciprofloxacin in paediatrics has been limited because of concerns regarding irreversible quinolone-induced arthropathy documented in juvenile animal models, although such effects have not been observed in children despite extensive use.^{89–91} Ciprofloxacin suspension is licensed for other indications in children over two years of age⁹² and has been recommended for prophylaxis against meningococcal disease in adults and children.⁸⁷

Hib vaccination

The current UK infant immunisation programme recommends a dose of Hib-containing vaccine at two, three and four months of age, followed by a booster dose at 12 months (STRONGLY RECOMMENDED). The choice of Hib-containing vaccine to be used at different ages will depend on what other immunisation the child has already received and on the availability of suitable preparations. Two Hib-containing vaccines are currently available in the

UK: Pediacel® (diphtheria, tetanus, acellular pertussis, inactivated polio and Hib combination vaccine) which is recommended for infant immunisation, and Menitorix® (Hib and meningococcal C combination vaccine) which is recommended for booster doses at 12 months. Children younger than 10 years who have never been immunised against Hib should receive the following course (RECOMMENDED):

- *0–2 months*: await routine infant immunisation at two, three and four months, followed by the scheduled booster dose at 12 months.
- *3–9 months*: three doses of a Hib-containing vaccine at monthly intervals, followed by the scheduled booster dose at 12 months, which should be given at least a month after the last dose.
- *10 months*: two doses of a Hib-containing vaccine at monthly intervals, followed by the scheduled booster dose at 12 months, which should be given at least a month after the last dose.
- *11 months*: one dose of a Hib-containing vaccine followed by the scheduled booster dose at 12 months, which should be given at least a month after the last dose.
- *12 months and older*: one dose of a Hib-containing vaccine, which may be the scheduled booster dose at 12 months.

Recommendations

Action is only required if an individual fulfils the criteria for a *confirmed* or *probable* case and either (i) the index case is younger than 10 years old, or (ii) there is a vulnerable individual in the household.

Index case

Young children who develop invasive Hib disease (i.e., index case) have a low but significant risk of a second episode of serious Hib infection (especially if younger than one year of age) and are also more likely to become asymptomatic carriers and transmit the organism to others. Thus, all index cases younger than 10 years with *confirmed* or *probable* invasive Hib disease should receive rifampicin chemoprophylaxis prior to discharge from hospital (INDICATED). In addition index cases of all ages with *confirmed* or *probable* invasive Hib disease should receive rifampicin chemoprophylaxis (which may be administered to the index case at any time during their inpatient stay) if there is a vulnerable individual in the household (INDICATED).

Unimmunised and partially immunised index cases younger than 10 years should complete their primary course of immunisation (see *Hib immunisation* above) (STRONGLY RECOMMENDED). Where possible, fully vaccinated index cases younger than 10 years should have Hib antibodies measured around four weeks after infection and an additional dose of a Hib-containing vaccine given if antibody levels are below the recommended 1 µg/ml (RECOMMENDED). If it is not possible to measure anti-Hib antibody levels or if there are concerns that the child might be lost to follow-up, then index cases older than 12 months and younger than 10 years (irrespective of their Hib vaccination status) should receive an extra dose of a Hib-containing vaccine prior to hospital

discharge in order to ensure high levels of anti-Hib antibodies and long-term protection against Hib.^{5,93} Infants aged 5–10 months who have been appropriately vaccinated at two, three and four months, should also receive one dose of a Hib-containing vaccine prior to discharge from hospital to provide adequate protection until they receive their routine 12-month booster dose (RECOMMENDED). Index cases of any age with asplenia or splenic dysfunction who are previously unimmunised or partially immunised should complete immunisation according to national recommendations, while those who have previously completed vaccination against Hib with the final dose more than one year previously should receive an extra dose of the vaccine after recovering from their infection (INDICATED).¹

Finally, children who develop invasive Hib disease after being fully vaccinated (particularly those who have received four doses of a Hib-containing vaccine) should have their anti-Hib antibody levels measured before and after re-vaccination with a Hib-containing vaccine once they have recovered from their infection. These children should also have total immunoglobulin levels and subclasses measured, and be carefully assessed for evidence of an immune deficiency (RECOMMENDED).

Household contacts

Household contacts of index cases, especially young children and those with underlying medical problems such as immunosuppression and asplenia, are at significantly higher risk of developing invasive Hib disease than the general population. Therefore, all household contacts of the index case with *confirmed* or *probable* invasive Hib disease should receive chemoprophylaxis if there is a vulnerable individual in the household (RECOMMENDED). In such situations, the index case should also receive chemoprophylaxis irrespective of age. Chemoprophylaxis should be given as soon as the diagnosis of Hib is confirmed in the index case (RECOMMENDED). If there is likely to be a >48 h delay in obtaining *H. influenzae* serotype results, then antibiotic prophylaxis should be given immediately to household contacts if the index case is considered to be a *probable case* of Hib and there is a vulnerable individual in the household (INDICATED). If there is a delay in obtaining *H. influenzae* serotype results and the index case is not considered to be a *probable case* of Hib, but a subsequent serotype result within four weeks of illness confirms Hib infection in the index case, then antibiotic prophylaxis should be given immediately to household contacts if there is a vulnerable individual in the household (INDICATED).

In addition, unimmunised and partially immunised children younger than 10 years should complete their primary immunisation (see *Hib vaccination* above) (STRONGLY RECOMMENDED), while those who only received three doses of Hib vaccine in infancy should receive an extra dose of the vaccine as soon as possible (RECOMMENDED). If this extra dose is delivered under 12 months of age, then the routine booster dose of Hib-containing vaccine should be given at 12 months of age, with an interval of at least one month between the two doses (INDICATED). Individuals of any age with asplenia or splenic dysfunction who are previously unimmunised or partially immunised should complete immunisation according to national recommendations.¹ Individuals in this group who

have previously completed vaccination against Hib with the final dose more than one year previously, should receive an extra dose of the vaccine as soon as possible (INDICATED). The opportunity should also be taken to ensure that all household contacts younger than 10 years are up-to-date with their other routine immunisations (STRONGLY RECOMMENDED).

Contacts in the pre-school or primary school setting

For all index cases younger than 10 years of age, the families of children attending the same pre-school group or primary school as the index case should be informed that they should seek medical advice if their child develops a fever and/or becomes unwell (INDICATED). For settings where a group of children who have levels of contact approaching those in the household can be defined – for example, a small number of children attending the same child-minder for several hours each day – offering prophylaxis to the close contact group should be considered. Families should also be encouraged to ensure that their children are up-to-date with all their immunisations (STRONGLY RECOMMENDED). In case of an outbreak (two or more cases of Hib disease within 120 days), as well as the above, chemoprophylaxis should be offered to all room contacts, including staff (RECOMMENDED). In addition, unimmunised and partially immunised children younger than 10 years should complete their primary immunisation (see *Hib vaccination* above) (RECOMMENDED) and those who received only the infant Hib immunisation schedule at two, three and four months should receive an extra dose of the vaccine as soon as possible (RECOMMENDED).

Conclusions

The introduction of the Hib conjugate vaccine into national infant immunisation programmes has dramatically reduced the incidence of invasive Hib disease across all age groups. However, breakthrough cases do occur and can potentially transmit the organism to susceptible individuals. A short course of Rifampicin remains highly effective in eliminating asymptomatic carriage, thereby reducing the risk of invasive Hib disease. The new prevention guidelines take into account the changes in the epidemiology of Hib disease following the introduction of the Hib conjugate vaccine, the shifts in the age-specific susceptibility of Hib disease, antibiotic susceptibility of the organism and current empiric antibiotic treatment of serious bacterial infections in adults and children.

Acknowledgements

The authors would like to thank Dr Amelia Cummins, CCDC, for her constructive comments regarding the manuscript.

References

1. *Haemophilus influenzae* type b (Hib). In: Salisbury DM, Ramsay ME, Noakes K, editors. *Immunisation against infectious disease*. 3rd ed. London: The Stationary Office; 2006. p. 127–42.
2. Booy R. Getting Hib vaccine to those who need it. *Lancet* 1998; **351**:1446–7.
3. Peltola H. Worldwide *Haemophilus influenzae* type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clin Microbiol Rev* 2000; **13**:302–17.
4. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating *Haemophilus influenzae* type b vaccine effectiveness in England and Wales by use of the screening method. *J Infect Dis* 2003; **188**:481–5.
5. Heath PT, Booy R, Azzopardi HJ, Slack MP, Bowen-Morris J, Griffiths H, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. *JAMA* 2000; **284**:2334–40.
6. Heath PT, McVernon J. The UK Hib vaccine experience. *Arch Dis Child* 2002; **86**:396–9.
7. Fogarty J, Moloney AC, Newell JB. The epidemiology of *Haemophilus influenzae* type b disease in the Republic of Ireland. *Epidemiol Infect* 1995; **114**:451–63.
8. Herczeg A. The decline of *Haemophilus influenzae* type b disease in Australia. *Commun Dis Intell* 1997; **21**:173–6.
9. Garpenholt O, Silfverdal SA, Hugosson S, Fredlund H, Bodin L, Romanus V, et al. The impact of *Haemophilus influenzae* type b vaccination in Sweden. *Scand J Infect Dis* 1996; **28**:165–9.
10. Hargreaves RM, Slack MP, Howard AJ, Anderson E, Ramsay ME. Changing patterns of invasive *Haemophilus influenzae* disease in England and Wales after introduction of the Hib vaccination programme. *BMJ* 1996; **312**:160–1.
11. Baker M, Martin D. Hib disease rate plummets following immunisation programme. *N Z Public Health Rep* 1995; **2**:13–4.
12. Cartwright KA, Begg NT, Hull D. Chemoprophylaxis for secondary *Haemophilus influenzae* type b disease. *CDR (Lond Engl Rev)* 1991; **1**:R2–6.
13. Cartwright KA, Begg NT, Rudd PT. Use of vaccines and antibiotic prophylaxis in contacts and cases of *Haemophilus influenzae* type b (Hib) disease. *Commun Dis Rep CDR Rev* 1994; **4**:R16–17.
14. Anderson EC, Begg NT, Crawshaw SC, Hargreaves RM, Howard AJ, Slack MP. Epidemiology of invasive *Haemophilus influenzae* infections in England and Wales in the pre-vaccination era (1990–2). *Epidemiol Infect* 1995; **115**:89–100.
15. Booy R, Hodgson S, Carpenter L, Mayon-White RT, Slack MP, Macfarlane JA, et al. Efficacy of *Haemophilus influenzae* type b conjugate vaccine PRP-T. *Lancet* 1994; **344**:362–6.
16. Eskola J, Peltola H, Takala AK, Kayhty H, Hakulinen M, Karanko V, et al. Efficacy of *Haemophilus influenzae* type b polysaccharide–diphtheria toxoid conjugate vaccine in infancy. *N Engl J Med* 1987; **317**:717–22.
17. Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate *Haemophilus influenzae* type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. *Pediatr Infect Dis J* 1991; **10**:97–104.
18. McVernon J, Trotter CL, Slack MP, Ramsay ME. Trends in *Haemophilus influenzae* type b infections in adults in England and Wales: surveillance study. *BMJ* 2004; **329**:655–8.
19. Sarangi J, Cartwright K, Stuart J, Brookes S, Morris R, Slack M. Invasive *Haemophilus influenzae* disease in adults. *Epidemiol Infect* 2000; **124**:441–7.
20. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in *Haemophilus influenzae* serotype b (Hib) disease following implementation of a booster campaign. *Arch Dis Child* 2008; **93**:665–9.
21. McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after *Haemophilus influenzae* type b (Hib) combination vaccines with acellular pertussis. *Lancet* 2003; **361**:1521–3.
22. Greenberg DP, Wong VK, Partridge S, Chang SJ, Jing J, Howe BJ, et al. Immunogenicity of a *Haemophilus influenzae* type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria–tetanus–acellular pertussis–hepatitis B combination vaccine. *Pediatr Infect Dis J* 2000; **19**:1135–40.

23. Heath PT, Ramsay ME. *Haemophilus influenzae* type b vaccine—booster campaign. *BMJ* 2003;**326**:1158–9.
24. Gessner BD, Sutanto A, Steinhoff M, Soewignjo S, Widjaya A, Nelson C, et al. A population-based survey of *Haemophilus influenzae* type b nasopharyngeal carriage prevalence in Lombok Island, Indonesia. *Pediatr Infect Dis J* 1998;**17**:S179–82.
25. Gomez E, Moore A, Sanchez J, Kool J, Castellanos PL, Feris JM, et al. The epidemiology of *Haemophilus influenzae* type b carriage among infants and young children in Santo Domingo, Dominican Republic. *Pediatr Infect Dis J* 1998;**17**:782–6.
26. Kuroki H, Ishikawa N, Uehara S, Himi K, Sonobe T, Niimi H. Nasopharyngeal colonization with *Haemophilus influenzae* type b among infants and children in Japan. *Acta Paediatr Jpn* 1997;**39**:541–5.
27. Olsen SJ, Dejsirilert S, Sangsuk L, Chunsutiwat S, Dowell SF. Frequent *Haemophilus influenzae* type B colonization in rural Thailand. *Pediatr Infect Dis J* 2005;**24**:739–42.
28. Howard AJ, Dunkin KT, Millar GW. Nasopharyngeal carriage and antibiotic resistance of *Haemophilus influenzae* in healthy children. *Epidemiol Infect* 1988;**100**:193–203.
29. Daum RS, Glode MP, Goldmann DA, Halsey N, Ambrosino D, Welborn C, et al. Rifampin chemoprophylaxis for household contacts of patients with invasive infections due to *Haemophilus influenzae* type b. *J Pediatr* 1981;**98**:485–91.
30. Andersson von Rosen I, Gotherfors L, Schmeisser S, Tarnvik A, Svanborg EC. Outbreak of *Haemophilus influenzae* type b meningitis in a day care center. *Pediatr Infect Dis J* 1990;**9**:326–32.
31. Murphy TV, Granoff D, Chrane DF, Olsen KD, Barenkamp SJ, Dowell SF, et al. Pharyngeal colonization with *Haemophilus influenzae* type b in children in a day care center without invasive disease. *J Pediatr* 1985;**106**:712–6.
32. Gilbert GL, MacInnes SJ, Guise IA. Rifampicin prophylaxis for throat carriage of *Haemophilus influenzae* type b in patients with invasive disease and their contacts. *BMJ* 1991;**302**:1432–5.
33. Cochi SL, Fleming DW, Hightower AW, Limpakarnjanarat K, Facklam RR, Smith JD, et al. Primary invasive *Haemophilus influenzae* type b disease: a population-based assessment of risk factors. *J Pediatr* 1986;**108**:887–96.
34. Li Ki, Dashefsky B, Wald ER. *Haemophilus influenzae* type b colonization in household contacts of infected and colonized children enrolled in day care. *Pediatrics* 1986;**78**:15–20.
35. Glode MP, Daum RS, Boies EG, Ballard TL, Murray M, Granoff DM. Effect of rifampin chemoprophylaxis on carriage eradication and new acquisition of *Haemophilus influenzae* type b in contacts. *Pediatrics* 1985;**76**:537–42.
36. Murphy TV, Chrane DF, McCracken Jr GH, Nelson JD. Rifampin prophylaxis v placebo for household contacts of children with *Haemophilus influenzae* type b disease. *Am J Dis Child* 1983;**137**:627–32.
37. Band JD, Fraser DW, Hightower AW, Broome CV. Prophylaxis of *Haemophilus influenzae* type b disease. *JAMA* 1984;**252**:3249–50.
38. Shapiro ED, Wald ER. Efficacy of rifampin in eliminating pharyngeal carriage of *Haemophilus influenzae* type b. *Pediatrics* 1980;**66**:5–8.
39. Barbour ML, Booy R, Crook DW, Griffiths H, Chapel HM, Moxon ER, et al. *Haemophilus influenzae* type b carriage and immunity four years after receiving the *Haemophilus influenzae* oligosaccharide-CRM197 (HbOC) conjugate vaccine. *Pediatr Infect Dis J* 1993;**12**:478–84.
40. Takala AK, Eskola J, Leinonen M, Kayhty H, Nissinen A, Pekkanen E, et al. Reduction of oropharyngeal carriage of *Haemophilus influenzae* type b (Hib) in children immunized with an Hib conjugate vaccine. *J Infect Dis* 1991;**164**:982–6.
41. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of *Haemophilus influenzae* type b. *J Infect Dis* 1995;**171**:93–8.
42. Castillo-Febres O, Lopez G, Ortegale F, Estopinán M, Casanova-Escalona L, Sanchez-Naveda M, et al. Oropharyngeal carriers in Venezuelan children in two child care settings, vaccinated or not with *Haemophilus influenzae* type b-tetanus toxoid conjugate vaccine (PRP-T). *Invest Clin* 2005;**46**:15–24.
43. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a *Haemophilus influenzae* type b conjugate vaccine reduces oropharyngeal carriage of *Haemophilus influenzae* type b among Gambian children. *J Infect Dis* 1998;**177**:1758–61.
44. McVernon J, Howard AJ, Slack MP, Ramsay ME. Long-term impact of vaccination on *Haemophilus influenzae* type b (Hib) carriage in the United Kingdom. *Epidemiol Infect* 2004;**132**:765–7.
45. Johnson NG, Ruggeberg JU, Balfour GF, Lee YC, Liddy H, Irving D, et al. *Haemophilus influenzae* type b reemergence after combination immunization. *Emerg Infect Dis* 2006;**12**:937–41.
46. Oh SY, Griffiths D, John T, Lee YC, Yu LM, McCarthy N, et al. School-aged children: a reservoir for continued circulation of *Haemophilus influenzae* type b in the United Kingdom. *J Infect Dis* 2008;**197**:1275–81.
47. Brenneman G, Silimperi D, Ward J. Recurrent invasive *Haemophilus influenzae* type b disease in Alaskan natives. *Pediatr Infect Dis J* 1987;**6**:388–92.
48. Edmonson MB, Granoff DM, Barenkamp SJ, Chesney PJ. Outer membrane protein subtypes and investigation of recurrent *Haemophilus influenzae* type b disease. *J Pediatr* 1982;**100**:202–8.
49. Cates KL, Krause PJ, Murphy TV, Stutman HR, Granoff DM. Second episodes of *Haemophilus influenzae* type b disease following rifampin prophylaxis of the index patients. *Pediatr Infect Dis J* 1987;**6**:512–5.
50. Liston TE. Pathogenesis and prevention of recurrent infection after *Haemophilus influenzae* bacteremia. *Clin Pediatr (Phila)* 1984;**23**:215–9.
51. Band JD, Fraser DW, Ajello G. Prevention of *Haemophilus influenzae* type b disease. *JAMA* 1984;**251**:2381–6.
52. Glode MP, Daum RS, Goldmann DA, Leclair J, Smith A. *Haemophilus influenzae* type B meningitis: a contagious disease of children. *Br Med J* 1980;**280**:899–901.
53. Campbell LR, Zedd AJ, Michaels RH. Household spread of infection due to *Haemophilus influenzae* type b. *Pediatrics* 1980;**66**:115–7.
54. Granoff DM, Basden M. *Haemophilus influenzae* infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. *J Infect Dis* 1980;**141**:40–6.
55. Ward JI, Fraser DW, Baraff LJ, Plikaytis BD. *Haemophilus influenzae* meningitis. A national study of secondary spread in household contacts. *N Engl J Med* 1979;**301**:122–6.
56. Filice GA, Andrews Jr JS, Hudgins MP, Fraser DW. Spread of *Haemophilus influenzae*. Secondary illness in household contacts of patients with *Haemophilus influenzae* meningitis. *Am J Dis Child* 1978;**132**:757–9.
57. Murphy TV, Clements JF, Breedlove JA, Hansen EJ, Seibert GB. Risk of subsequent disease among day-care contacts of patients with systemic *Haemophilus influenzae* type B disease. *N Engl J Med* 1987;**316**:5–10.
58. Osterholm MT, Pierson LM, White KE, Libby TA, Kuritsky JN, McCullough JG. The risk of subsequent transmission of *Haemophilus influenzae* type B disease among children in day care. Results of a two-year statewide prospective surveillance and contact survey. *N Engl J Med* 1987;**316**:1–5.
59. Fleming DW, Leibenhaut MH, Albanes D, Cochi SL, Hightower AW, Makintubee S, et al. Secondary *Haemophilus influenzae* type b in day-care facilities. Risk factors and prevention. *JAMA* 1985;**254**:509–14.
60. Rijkers GT, Vermeer-de Bondt PE, Spanjaard L, Breukels MA, Sanders EA. Return of *Haemophilus influenzae* type b infections. *Lancet* 2003;**361**:1563–4.

61. Spanjaard L, van den HS, de Melker HE, Vermeer-de Bondt PE, van der EA, Rijkers GT. Increase in the number of invasive *Haemophilus influenzae* type b infections. *Ned Tijdschr Geneesk* 2005;**149**:2738–42.
62. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. Antibody to *Haemophilus influenzae* type b after routine and catch-up vaccination. *Lancet* 2003;**361**:1523–4.
63. Cox F, Trinchler R, Rissing JP, Patton M, McCracken Jr GH, Granoff DM. Rifampin prophylaxis for contacts of *Haemophilus influenzae* type b disease. *JAMA* 1981;**245**:1043–5.
64. Gessert C, Granoff DM, Gilsdorf J. Comparison of rifampin and ampicillin in day care center contacts of *Haemophilus influenzae* type b disease. *Pediatrics* 1980;**66**:1–4.
65. Granoff DM, Gilsdorf J, Gessert C, Basden M. *Haemophilus influenzae* type B disease in a day care center: eradication of carrier state by rifampin. *Pediatrics* 1979;**63**:397–401.
66. Li KI, Wald ER. Use of rifampin in *Haemophilus influenzae* type b infections. *Am J Dis Child* 1986;**140**:381–5.
67. Yogev R. The taxonomy and antimicrobial susceptibility of *Haemophilus* species in clinical specimens. *Am J Clin Pathol* 1979;**72**:133–4.
68. Green M, Li KI, Wald ER, Guerra N, Byers C. Duration of rifampin chemoprophylaxis for contacts of patients infected with *Haemophilus influenzae* type B. *Antimicrob Agents Chemother* 1992;**36**:545–7.
69. Yogev R, Melick C, Kabat K. Nasopharyngeal carriage of *Haemophilus influenzae* type b: attempted eradication by cefaclor or rifampin. *Pediatrics* 1981;**67**:430–3.
70. Rowley AH, Chadwick EG, Kabat K, Sroka P, Shulman ST, Yogev R. Failure of a single dose of ceftriaxone to eradicate nasopharyngeal colonization of *Haemophilus influenzae* type b. *J Pediatr* 1987;**110**:792–4.
71. Darouiche R, Perkins B, Musher D, Hamill R, Tsai S. Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria. *J Infect Dis* 1990;**162**:1124–7.
72. Michaels RH, Norden CW. Pharyngeal colonization with *Haemophilus influenzae* type b: a longitudinal study of families with a child with meningitis or epiglottitis due to *Haemophilus influenzae* type b. *J Infect Dis* 1977;**136**:222–8.
73. Ogle JW, Rabalais GP, Glode MP. Duration of pharyngeal carriage of *Haemophilus influenzae* type b in children hospitalized with systemic infections. *Pediatr Infect Dis* 1986;**5**:509–11.
74. Goldwater PN. Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal *Haemophilus influenzae* type b colonization in children. *Antimicrob Agents Chemother* 1995;**39**:2150–2.
75. Niederman MS, Anzueto A, Sethi S, Choudhri S, Kureishi A, Haverstock D, et al. Eradication of *Haemophilus influenzae* in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents. *Respir Med* 2006;**100**:1781–90.
76. Makintubee S, Istre GR, Ward JI. Transmission of invasive *Haemophilus influenzae* type b disease in day care settings. *J Pediatr* 1987;**111**:180–6.
77. Boies EG, Granoff DM, Squires JE, Barenkamp SJ. Development of *Haemophilus influenzae* type b meningitis in a household contact treated with rifampin. *Pediatrics* 1982;**70**:141–2.
78. Murphy TV, McCracken Jr GH, Moore BS, Gulig PA, Hansen EJ. *Haemophilus influenzae* type b disease after rifampin prophylaxis in a day care center: possible reasons for its failure. *Pediatr Infect Dis* 1983;**2**:193–8.
79. Wilde J, Adler SP. Molecular epidemiology of *Haemophilus influenzae* type B: failure of rifampin prophylaxis in a day care center. *Pediatr Infect Dis* 1986;**5**:505–8.
80. Gilbert GL. Epidemiology of *Haemophilus influenzae* type b disease in Australia and New Zealand. *Vaccine* 1991;**9**(Suppl.):S10–13.
81. Murphy TV, McCracken Jr GH, Zweighaft TC, Hansen EJ. Emergence of rifampin-resistant *Haemophilus influenzae* after prophylaxis. *J Pediatr* 1981;**99**:406–9.
82. McVernon J, Morgan P, Mallaghan C, Biswas T, Natarajan M, Griffiths D, et al. Outbreak of *Haemophilus influenzae* type b disease among fully vaccinated children in a day-care center. *Pediatr Infect Dis J* 2004;**23**:38–41.
83. Granoff DM, McKinney T, Boies EG, Steele NP, Oldfather J, Pandey JP, et al. *Haemophilus influenzae* type b disease in an Amish population: studies of the effects of genetic factors, immunization, and rifampin prophylaxis on the course of an outbreak. *Pediatrics* 1986;**77**:289–95.
84. Patterson JE, Madden GM, Krisiunas EP, Masecar B, Hierholzer Jr WJ, Zervos MJ, et al. A nosocomial outbreak of ampicillin-resistant *Haemophilus influenzae* type b in a geriatric unit. *J Infect Dis* 1988;**157**:1002–7.
85. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 2002;**51**:1–29.
86. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 2003;**52**:1–36.
87. Health Protection Agency Meningococcus Forum. Guidelines for public health management of meningococcal disease in the UK. Available at: <http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1194947389261>; 2006 [accessed October 2008].
88. Ladhani S, Heath PT, Ramsay ME, Slack MP. Changes in antibiotic resistance rates of invasive *Haemophilus influenzae* isolates in England and Wales over the last 20 years. *J Antimicrob Chemother* 2008;**62**:776–9.
89. Grady R. Safety profile of quinolone antibiotics in the pediatric population. *Pediatr Infect Dis J* 2003;**22**:1128–32.
90. Alghasham AA, Nahata MC. Clinical use of fluoroquinolones in children. *Ann Pharmacother* 2000;**34**:347–59.
91. Committee on Infectious Diseases. The use of systemic fluoroquinolones. *Pediatrics* 2006;**118**:1287–92.
92. Anonymous. *BNF for children 2007*. BMJ Publishing Group Ltd.; 2007.
93. Heath PT, Booy R, Griffiths H, Clutterbuck E, Azzopardi HJ, Slack MP, et al. Clinical and immunological risk factors associated with *Haemophilus influenzae* type b conjugate vaccine failure in childhood. *Clin Infect Dis* 2000;**31**:973–80.
94. Ward JI, Margolis HS, Lum MK, Fraser DW, Bender TR, Anderson P. *Haemophilus influenzae* disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. *Lancet* 1981;**1**:1281–5.
95. Levine OS, Liu G, Garman RL, Dowell SF, Yu S, Yang YH. *Haemophilus influenzae* type b and *Streptococcus pneumoniae* as causes of pneumonia among children in Beijing, China. *Emerg Infect Dis* 2000;**6**:165–70.
96. Kristensen K. Carriage and antibiotic susceptibility of *Haemophilus influenzae* type b and non-b in Danish day-care attendees. *APMIS* 1990;**98**:50–2.
97. Sung RY, Ling JM, Fung SM, Oppenheimer SJ, Crook DW, Lau JT, et al. Carriage of *Haemophilus influenzae* and *Streptococcus pneumoniae* in healthy Chinese and Vietnamese children in Hong Kong. *Acta Paediatr* 1995;**84**:1262–7.
98. Manary MJ, Lehmann D, Michael A, Coakley K, Taima J, Montgomery J, et al. Antigenuria in healthy Papua New Guinea children with nasal *Haemophilus influenzae* type b carriage. *Ann Trop Paediatr* 1993;**13**:385–9.
99. Bakir M, Yagci A, Ulger N, Akbenlioglu C, Ilki A, Soyletir G, et al. Pharyngeal colonization with *Haemophilus influenzae* type b among healthy Turkish infants and children. *Pediatr Int* 2002;**44**:381–6.
100. Ayyildiz A, Aktas AE, Yazgi H. Nasopharyngeal carriage rate of *Haemophilus influenzae* in children aged 7–12 years in Turkey. *Int J Clin Pract* 2003;**57**:686–8.